单克隆抗体BG_6及多克隆抗体CEA对乳腺癌的联合诊断价值

The diagnostic value of monoclonal antibody BG6 and polyclonal antibody CEA combined in mammary carcinoma

测定５１例乳腺癌，１５例良性乳腺疾病及１７例各种其它良、恶性疾病，结果显示：抗人乳腺癌单克隆抗体ＢＧ＿６特异性较强，但诊断阳性率仅为７６．７％，如与多克隆抗体ＣＥＡ联合使用，可大大提高其阳性率，即两种抗体交叉阳性率可达９６％．在乳腺癌类型中，恶性度较大的单纯癌、硬癌及浸润型导管癌，ＢＧ＿６阳性率表达显著高于其它类型。对少数乳腺腺病及囊性增生症病例中出现阳性，可能反映乳腺上皮的癌变过程。

Abstract We examined 51 cases with mammary carcinoma, 15 eases with benign mammary disease and other benign or malignant mammary disease, As a result the monoclonal antibody BG6 for antihuman mammary carcinoma had a relatively great speciality, but the positive rate was only 76. 7 %. If BG6 and CEA could be used simeltaneously, the overlap positive rate might be raised 96 %. Among these types of mammary carcinoma, the higher the malighant grade, the higher is the positive rate of BG6. Therefor, Such .as adenocarcinoma simplex. scirrhous adenocarcinoma, and infiltrate ductal adenocarcinoma, its positive rate of BG6 appears higher than other types. Sometimes a few mammary adenosis and mammary cystic hyperplasia showed also positive reaction, It probably was malignancy of those mammary disease.